Table 4.
Longitudinal associations between treatment-related factors and executive function symptoms in 330 cancer survivors with different cancer diagnoses
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
|---|---|---|---|---|---|
| Intercept | 19.14 (17.37, 20.90)*** | 19.60 (16.79, 22.40)*** | 12.71 (3.30, 22.11)** | 16.04 (5.16, 26.93)** | 10.13 (− 0.80, 21.05) |
| Time | |||||
| Baseline | Ref | Ref | Ref | Ref | Ref |
| 6 months | − 0.21 (− 1.79, 1.38) | − 0.15 (− 1.72, 1.41) | − 0.19 (− 1.77, 1.39) | − 0.40 (− 1.95, 1.16) | 0.25 (− 1.30, 1.79) |
| 12 months | − 0.04 (− 1.58, 1.50) | 0.03 (− 1.54, 1.60) | 0.11 (− 1.47, 1.68) | 0.07 (− 1.54, 1.67) | 0.54 (− 1.06, 2.14) |
| 18 months | 0.11 (− 1.44, 1.66) | 0.20 (− 1.37, 1.78) | 0.22 (− 1.36, 1.80) | 0.18 (− 1.42, 1.78) | 0.55 (− 1.04, 2.15) |
| Type of cancer treatment | |||||
| Locoregional treatment | Ref | Ref | Ref | Ref | |
| Chemotherapy | − 1.94 (− 5.33, 1.46) | − 2.32 (− 5.82, 1.19) | − 4.52 (− 8.34, − 0.70)* | − 4.05 (− 7.75, − 0.35)* | |
| Other systemic therapy1 | 7.83 (1.48, 14.17)* | 7.78 (1.49, 14.06)* | 8.35 (1.30, 15.40)* | 7.97 (0.95, 14.99)* | |
| Gender | |||||
| Male | Ref | Ref | Ref | ||
| Female | 2.34 (− 0.88, 5.56) | 0.41 (− 3.39, 4.20) | 0.50 (− 3.17, 4.17) | ||
| Age | 0.08 (− 0.10, 0.25) | 0.02 (− 0.16, 0.20) | 0.05 (− 0.12, 0.23) | ||
| Education | |||||
| High | Ref | Ref | Ref | ||
| Medium | 4.66 (1.07, 8.25)* | 4.27 (0.61, 7.94)* | 4.12 (0.57,7.67)* | ||
| Low | 0.84 (− 3.19, 4.86) | 0.85 (− 3.20, 4.90) | 1.02 (− 2.95, 4.99) | ||
| Treatment completed | |||||
| Yes | Ref | Ref | |||
| No | 1.15 (− 2.80, 5.11) | 1.05 (− 2.84, 4.95) | |||
| Time diagnosis to RTW a | − 0.29 (− 0.53, − 0.06)* | − 0.26 (− 0.49, − 0.03)* | |||
| Extent of disease | |||||
| Local | Ref | Ref | |||
| Regional | 1.35 (− 2.86, 5.57) | 1.35 (− 2.76, 5.46) | |||
| Distant | − 0.97 (− 11.43, 9.49) | − 1.27 (− 11.21, 8.66) | |||
| Unknown | − 2.53 (− 6.82, 1.77) | − 2.72 (− 6.88, 1.45) | |||
| Depressive symptoms b | 0.08 (− 0.03, 0.18) | ||||
| Fatigue c | 0.13 (0.03, 0.24)* | ||||
Note: * p value < 0.05; ** p value < 0.01; *** p value < 0.001. Intercept, slopes, and 95% confidence intervals were presented. 1Other “systemic” therapy using hormonal therapy or targeted therapy, exclusively or in combination with surgery and/or radiotherapy. RTW, return to work; a in months; b range 0–28; c range 8–56. Model 1 included n = 1084 (82.1%); Model 2 n = 1067 (80.8%); Model 3 n = 1060 (80.3%); Model 4 n = 1024 (77.6%.); Model 5 n = 1023 (77.5%) of the 1320 possible person-measurement observations